降压药服药时间与心血管事件及死亡:BedMed随机临床试验
BedMed是一项多中心、开放标签、实用性随机临床试验,通过5个加拿大省份的436名初级保健医生招募社区居住的成人高血压患者,随机分配为睡前服用所有每日一次降压药(n=1677)或早晨服用(n=1680)。中位随访4.6年,主要复合终点(全因死亡或卒中、急性冠脉综合征、心力衰竭住院/急诊就诊)发生率睡前组为2.3/100患者年,早晨组为2.4/100患者年(校正HR 0.96;95%CI 0.77-1.19;P=0.70)。主要终点的各组成部分、全因住院/急诊就诊及安全性结局(包括跌倒或骨折、新发青光眼诊断、18个月认知下降)两组均无差异。结论认为睡前服用降压药安全但未降低心血管风险,服药时间不影响降压治疗的风险与获益,应按患者偏好决定。
要点
- 在初级保健高血压成人中,睡前服用降压药与早晨服用相比,主要心血管复合终点发生率无显著差异(校正HR 0.96;95%CI 0.77-1.19;P=0.70)。
- 睡前组主要复合终点发生率为2.3/100患者年,早晨组为2.4/100患者年。
- 主要终点的各组成部分、全因住院/急诊就诊及安全性结局(跌倒或骨折、新发青光眼诊断、18个月认知下降)两组均无差异。
- 睡前服用降压药安全,但未降低心血管风险,服药时间应按患者偏好决定。
适用人群与场景
- 社区居住的成人高血压患者,正在服用至少1种每日一次降压药,由5个加拿大省份的436名初级保健医生招募。
- 招募时间2017年3月31日至2022年5月26日,最终随访2023年12月22日。
研究设计与关键结果
- 多中心、开放标签、实用性随机临床试验,盲法终点评估,3357名成人随机(睡前组n=1677,早晨组n=1680),中位随访4.6年。
- 主要复合终点(全因死亡或卒中、急性冠脉综合征、心力衰竭住院/急诊就诊)发生率:睡前组2.3/100患者年 vs 早晨组2.4/100患者年(校正HR 0.96;95%CI 0.77-1.19;P=0.70)。
- 主要终点的各组成部分、全因住院/急诊就诊及安全性结局(跌倒或骨折、新发青光眼诊断、18个月认知下降)两组均无差异。
- 56.4%为女性,中位年龄67岁,53.7%接受单药治疗。
证据类型、等级与局限
- 证据类型:多中心、开放标签、实用性随机临床试验,盲法终点评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于初级保健中的高血压成人,睡前服用降压药是安全的,但未降低心血管风险;服药时间不影响降压治疗的风险与获益,应按患者偏好决定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Whether administration of blood pressure medications at bedtime instead of in the morning reduces cardiovascular risk is unknown, as findings from large clinical trials have not been consistent. There is also concern that bedtime antihypertensive use could induce glaucoma-related visual loss or other hypotensive/ischemic adverse effects.
OBJECTIVE: To determine the effect of bedtime vs morning administration of antihypertensive medications on major cardiovascular events and death.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, pragmatic randomized clinical trial with blinded end-point assessment and recruitment via 436 primary care clinicians across 5 Canadian provinces inviting their community-dwelling adult patients with hypertension taking at least 1 once-daily antihypertensive medication. Participants were recruited from March 31, 2017, to May 26, 2022, with final follow-up on December 22, 2023.
INTERVENTIONS: Participants were randomized in a 1:1 ratio to using all once-daily antihypertensive medications either at bedtime (intervention group; n = 1677) or in the morning (control group; n = 1680).
MAIN OUTCOMES AND MEASURES: The primary outcome was time to first occurrence of all-cause death or hospitalization/emergency department (ED) visit for stroke, acute coronary syndrome, or heart failure. All-cause unplanned hospitalizations/ED visits, and visual, cognitive, and fall- and/or fracture-related safety outcomes were also assessed.
RESULTS: A total of 3357 adults (56.4% female; median age, 67 years; 53.7% taking monotherapy) were randomized and followed up for a median of 4.6 years in each treatment group. The composite primary outcome event occurred at a rate of 2.3 per 100 patient-years in the bedtime group and 2.4 per 100 patient-years in the morning group (adjusted hazard ratio, 0.96; 95% CI, 0.77-1.19; P = .70). Individual components of the primary outcome, all-cause hospitalizations/ED visits, and safety outcomes did not differ between groups. In particular, there was no difference in falls or fractures, new glaucoma diagnoses, or 18-month cognitive decline.
CONCLUSIONS AND RELEVANCE: Among adults with hypertension in primary care, bedtime administration of antihypertensive medications was safe but did not reduce cardiovascular risk. Antihypertensive medication administration time did not affect the risks and benefits of blood pressure-lowering medication and instead should be guided by patient preferences.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02990663.
参考来源
- Garrison SR, Bakal JA, Kolber MR, et al. Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial. JAMA. 2025. PMID: 40354045. doi:10.1001/jama.2025.4390
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。